STTK Shattuck Labs, Inc.
Shattuck Labs, Inc. (STTK) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.09 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.3% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Shattuck Labs, Inc.
Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company's wholly owned program includes SL-172154. It operates principally in Durham, North Carolina and Austin, Texas. Shattuck Labs Inc. is based in Austin, United States.
Sector
Healthcare
Industry
Biotechnology